AUG 10, 2026 · PHASE 3 TRIAL
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
ClinicalTrials.gov
This is an active Phase 3 trial registration with no results posted; the study is ongoing and has not yet reported efficacy or safety outcomes.
Reported
Planned sample size5511
Primary outcome measureInvasive breast cancer-free survival (IBCFS)
Follow-up durationUp to 14 years